Shaft Mucker Design

The mucking principle employed in the design of this mucking machine is that of a continuous operation instead of an intermittent one. The mucker was primarily designed for operation in shafts (vertical or inclined) and winzes but the mucker is not restricted to these

Savanna burning and the assessment of long-term fire experiments with particular reference to Zimbabwe

Long-term fire experiments in savannnas are rare, given the difficulties and demands of operation. Controlled fire experiments date from colonial times in West Africa, although the largest and best-known is located in the Kruger National Park, South Africa. The achievements of these experiments are assessed from examples in Africa, South America and Australia. A less well-known experiment in Zimbabwe was sited at the Marondera Grassland Research Station and ran from 1953 to 1991. Some of the preliminary results on the impact of fire on vegetation are analysed and compared with further vegetation surveys in 2007. Studies on tree growth in this miombo savanna woodland indicate that the plots burned at three- and four-year intervals recovered to greater mean heights than the unburned control plots. There was no significant variation between treatments, suggesting that the few trees that did survive in the frequently burned plots were large specimens. Brachystegia and Julbernadia dominated the plots throughout and after the experiment. Basal area and stocking density were highest in the four-yearly burned plots but there was a high variability throughout the experiment, suggesting that many trees may have attained heights and bark thicknesses sufficient to protect from fire damage. Fire also affected the composition of the herbaceous plant community, but not the number of species. By the end of the experiment some grass and sedge species had flourished while others revealed greater susceptibility to fire, and fire-tolerant species predominated in the most frequently burned areas. The experimental design appeared to cope well with the variability between plots and indicated the soundness of the initial design and its implementation

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)

bii4africa dataset

The bii4africa dataset is presented in a multi-spreadsheet .xlsx file. The raw data spreadsheet (‘Scores_Raw’) includes 31,313 individual expert estimates of the impact of a sub-Saharan African land use on a species response group of terrestrial vertebrates or vascular plants. Estimates are reported as intactness scores - the remaining proportion of an ‘intact’ reference (pre-industrial or contemporary wilderness area) population of a species response group in a land use, on a scale from 0 (no individuals remain) through 0.5 (half the individuals remain), to 1 (same as the reference population) and, in limited cases, to 2 (two or more times the reference population). For species that thrive in human-modified landscapes, scores could be greater than 1 but not exceeding 2 to avoid extremely large scores biasing aggregation exercises. Expert comments are included alongside respective estimates